SubscribeBiopharmaceuticals play a major role in today’s therapeutic field.
However, they pose significant drug delivery problems such as instability, efficacy and short half-life. The drug delivery of biopharmaceuticals can be improved by applying controlled release technologies based on polymeric systems, such as the technologies of OctoPlus.
The advantages that can be gained by these technologies include:
- Optimized pharmacokinetic profile (prevention of peak plasma concentrations);
- Reduced injection frequency;
- and possibly a safer and more efficacious therapy.
OctoPlus' controlled delivery systems encapsulate the active ingredient in a microsphere formed by the drug delivery polymer. After subcutaneous or intramuscular injection the polymer slowly degrades, releasing the drug gradually. An additional advantage might be protection of the (labile) drug against degradation.
OctoPlus has developed a number of proprietary drug delivery systems that facilitate controlled release for all classes of injectable compounds.
OctoDEX™: a dextran-based microsphere delivery technology for proteins and particulate systems. The system is also suitable for larger structures such as liposomes and cells, and shows promise for single-shot vaccine delivery.
In vitro-in vivo correlation of OctoDEX-TM-hGH in humans
Line with symbols: hGH serum levels after a single injection of OctoDEX-TM-hGH
Line without symbols: Prediction based on in vitro hGH release measurements
PolyActive™: a biodegradable polymeric drug delivery system for the controlled release of proteins and lipophilic small molecules.
SynBiosys™: a biodegradable polymeric drug delivery system for the controlled release of peptides and small molecules (in collaboration with Innocore BV, the Netherlands).
The technologies show excellent in vitro - in vivo correlation, making it possible to predict the release in vivo and to predict product potential and precise control over the release curve. We have developed cost-effective, robust and easily upscaleable manufacturing processes and have gathered robust safety data in animals.
Partner with OctoPlus
OctoPlus is globally recognised as an established player in the fields of drug delivery and formulation development, for example liposome formulation and formulation development of poorly soluble compounds. Our other capabilities include production of cGMP clinical trial material, process development and stability studies.
